Healthpeak Raises 2026 Guidance on Strong Outpatient Leasing; Lab Risks Linger

What happened

Healthpeak Properties' Q3 2026 results show net income of $0.02 per share and FFO as Adjusted of $0.44 per share, with outpatient medical leasing volumes of 846,000 square feet year-to-date, and the company raised full-year 2026 earnings guidance. The net income figure remains modest, reflecting elevated interest expense and residual lab-related impairments that have pressured reported earnings throughout 2025-2026. The increase in guidance signals that management sees better-than-expected operating performance, likely driven by the outpatient medical segment's strong lease execution and stable same-store NOI. However, the release omits granular lab occupancy or same-store NOI data, so the durability of the guidance raise relative to the lab cyclicality discussed in prior filings remains uncertain. Overall, the update is positive on the outpatient front but does not yet resolve the lab overhang that has capped valuation multiples.

Implication

Short-term, the raised guidance and strong outpatient leasing should support the stock near current levels and may narrow the discount to peers; however, the market will likely wait for lab stabilization before re-rating the shares materially. The $0.44 FFO as Adjusted for Q3 annualizes to ~$1.76, consistent with or slightly above prior full-year 2025 guidance, suggesting that the 2026 guidance raise is credible but not transformative. Investors should monitor upcoming disclosures for lab occupancy, same-store NOI by segment, and any further impairments, as these will determine whether the guidance increase reflects genuine broad-based improvement or simply outpatient offsetting continued lab weakness. For existing holders, the dividend remains covered at roughly 71% of AFFO per prior reports, and the raised guidance modestly improves margin of safety, but it does not eliminate the key risk of sustained lab oversupply pressuring future FFO. New investors should consider entering only on evidence that lab metrics have stabilized or at prices that already discount a prolonged lab downturn, rather than chasing the guidance headline.

Thesis delta

The investment thesis shifts incrementally positive: prior assumptions of low-single-digit FFO growth and contained lab headwinds are now supported by a raised 2026 earnings guidance and strong outpatient leasing. However, the persistent gap between net income and FFO as Adjusted, along with the absence of updated lab metrics, means the core risk of lab cyclicality remains unresolved. The stock's reward-to-risk profile improves modestly, but the thesis still hinges on lab stabilization over the next 12-18 months rather than a clear inflection.